FEDERAL VACCINE INJURY COMPENSATION COSTS OF $315 MIL
Executive Summary
FEDERAL VACCINE INJURY COMPENSATION COSTS OF $315 MIL. for up to 3,500 injuries caused by vaccines administered before the program effective date are estimated by the Congressional Budget Office. A preliminary version of the previous-injury funding proposal passed the House Ways & Means/Select Revenue Measures Subcommittee at a closed "conceptual markup" on July 13. The National Vaccine Injury Compensation Program, enacted in November, provides awards for up to 3,500 claimants for pre-effective date injuries. Based on CBO figures, the cost of the proposal in the first year alone could total $54 mil. A July 15 press release issued by the subcommittee states that compensation would be authorized with respect to vaccines administered before Oct. 1 of this year. The program will not be effective until separate funding legislation is passed. Under the subcommittee's plan, compensation would be drawn from a general revenues trust fund and subject to congressional appropriation, the subcommittee said. The plan will be considered next by the full House Ways & Means Committee as part of the committee's budget reconciliation legislation. Consideration is scheduled to begin the week of July 20. A funding plan for compensating future injuries through the establishment of a manufacturer's excise tax on vaccines was also considered at the session. However, the subcommittee agreed to delay action while discussions are held with Rep. Waxman's (D-Calif.) Energy & Commerce/Health Subcommittee on ways to ensure that the per-dose surcharge would remain under $5. Current CBO estimates put the per-dose surcharge for the diphtheria-pertussis-tetanus vaccine at $8.04. The measles-mumps-rubella surcharge is estimated at $7.84. Waxman's health subcommittee authored the compensation bill. Another funding mechanism for future claims, which was considered by the Ways & Means subcommittee, involved an entitlement program which would not be subject to annual appropriations by Congress.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth